CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics
Cells · 2026
DOI: 10.3390/cells15070644 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Adrianna Rutkowska und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland. Hauptthemen laut MEDLINE: CRISPR-Associated Protein 9, Gene Editing, Genetic Therapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 217 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LEK-AM Pharmaceutical Company Ltd, Medical University of Lodz, LEK-AM Pharmaceutical Company Ltd..
Abstract (Originalsprache)
CRISPR–Cas9 has progressed from an experimental tool to a therapeutic modality, marked by the first regulatory approvals of an ex vivo-edited autologous CD34+ hematopoietic stem cell product that induces fetal hemoglobin (CASGEVY/exa-cel). In this narrative review, we synthesize modality-specific molecular diagnostic strategies used across early CRISPR clinical translation. In parallel, early clinical experience has begun to demonstrate the feasibility of in vivo editing, including subretinal delivery for CEP290-associated inherited retinal degeneration (EDIT-101 programme) and hepatocyte-targeted lipid nanoparticles (LNPs) for liver-derived targets such as transthyretin and plasma prekallikrein (KLKB1). As translation expands across hematologic, metabolic, ocular and oncology indications, development is increasingly constrained by the predictability and safety of editing outcomes, delivery-determined biodistribution and exposure time, and immune recognition of bacterial Cas9 orthologs and delivery components. We summarize diagnostic readouts for confirming patient genotype, quantifying on-target editing and expression changes, assessing off-target and structural outcomes using orthogonal assays, and monitoring clonal dynamics and immune responses during long-term follow-up. We also discuss how these readouts interface with CMC controls and regulatory expectations for advanced therapy medicinal products (ATMPs), highlighting the need for fit-for-purpose, standardized testing frameworks in early trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland.
- Department of Research and Development, LEK-AM Pharmaceutical Company Ltd., Inwestycyjna 7 St., 95-050 Konstantynow Lodzki, Poland.
- Student Scientific Circle at the Department of Molecular Biology, Chair of Medical Biology, Medical University of Lodz, Zeligowskiego 7/9 St., 90-752 Lodz, Poland.
ORCID-Profile: Adrianna Rutkowska, Tadeusz Strózik, Tomasz Wasiak, Kamil Filiks, Maria Jaskólska
Förderung
- LEK-AM Pharmaceutical Company Ltd
- Medical University of Lodz
- LEK-AM Pharmaceutical Company Ltd.
Zitieren
APA
Rutkowska, A., Strózik, T., Wasiak, T., Ciunowicz, D., Kapelan, N., Szczepaniak, N., Sosnowski, J., Goślińska, W., Bartkowiak, J., Budny-Lewandowska, A., Antończyk, P., Markiewicz, M., Gustaw, P., Filiks, K., Jaskólska, M., & Stoczyńska-Fidelus, E. (2026). CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics. Cells. https://doi.org/10.3390/cells15070644
Vancouver
Rutkowska A, Strózik T, Wasiak T, Ciunowicz D, Kapelan N, Szczepaniak N, et al. CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics. Cells. 2026. doi:10.3390/cells15070644
BibTeX
@article{Rutkowska2026,
author = {Rutkowska, Adrianna and Strózik, Tadeusz and Wasiak, Tomasz and Ciunowicz, Damian and Kapelan, Natalia and Szczepaniak, Natalia and Sosnowski, Juliusz and Goślińska, Weronika and Bartkowiak, Jakub and Budny-Lewandowska, Agata and Antończyk, Patrycja and Markiewicz, Maria and Gustaw, Piotr and Filiks, Kamil and Jaskólska, Maria and Stoczyńska-Fidelus, Ewelina},
title = {CRISPR–Cas9 Therapeutics in Early Clinical Development: Delivery and Molecular Diagnostics},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15070644}
}
EUVIMED